The share of domestic drugs in public procurement amounted to almost 70%
"This year alone, more than 40 drugs for the treatment of oncological diseases have been registered. At the same time, more than half of the entire nomenclature of this segment is produced on a full cycle. And in general, the share of domestic drugs in public procurement in kind is already approaching 70%," Manturov said.
He stressed that the selling price of Russian analogues is often 1.5-2 times lower than that of imported ones. Thus, thanks to lenalidomide analogues produced by the companies "Biocad", "Pharmsintez" and "Biochemist", savings can reach 3 billion rubles a year. "This effect will be even more noticeable with the further substitution of imported medicines," Manturov added.